Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets genetic weakness in tough cancers

NCT ID NCT06915753

Recruiting now Disease control Sponsor: Tyra Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-stage trial tests a new daily pill called TYRA-430 in 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TYRA-430 (an oral drug that targets specific genetic changes in cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced liver cancer or other solid tumors that have certain genetic changes.
What could go wrong
This is a very early Phase 1 study, so the drug may not work or could have serious side effects. It is only for people with specific genetic changes, so it won't help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS FGF19 GENE AMPLIFICATION FGF19 GENE OVEREXPRESSION FGFR GENE ALTERATIONS FGFR GENE AMPLIFICATION FGFR3 GENE ALTERATION FGFR3 GENE FUSIONS FGFR3 GENE MUTATION FGFR4 GENE FUSIONS FGFR4 GENE MUTATION LOCALLY ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA METASTATIC HEPATOCELLULAR CARCINOMA SOLID TUMOR, ADULT SOLID TUMORS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, South Korea

  • Columbia University Irving Medical Center

    RECRUITING

    New York, New York, 10043, United States

  • John Hopkins University

    RECRUITING

    Baltimore, Maryland, 21205, United States

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Mass General Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

  • Sarah Cannon Research Institute Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    RECRUITING

    Seoul, South Korea

  • Stanford Cancer Institute

    RECRUITING

    Stanford, California, 94305, United States

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan

  • The University of Kansas Medical Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • UCSF Medical Center at Mount Zion

    RECRUITING

    San Francisco, California, 94158, United States

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • University Health Network Princess Margaret Cancer Center

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.